11 Pulmonary Fibrosis Clinical Trials in Birmingham, AL (2026)

Q: How do I join a clinical trial in Birmingham?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you.

Recruiting Pulmonary Fibrosis Studies in Birmingham

NCT01915511Recruiting

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to inc...

Birmingham, AL3,000 participantsDuke University

View Study Details

NCT06238622Recruiting

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medic...

Birmingham, ALPHASE31,700 participantsBoehringer Ingelheim

View Study Details

NCT05943535Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period....

Birmingham, ALPHASE3698 participantsUnited Therapeutics

View Study Details

NCT06806592Recruiting

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improve...

Birmingham, ALPHASE3400 participantsBoehringer Ingelheim

View Study Details

NCT07652658Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nint...

Birmingham, ALPHASE2359 participantsAstraZeneca

View Study Details

NCT06951217Recruiting

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants ...

Birmingham, ALPHASE2340 participantsAvalyn Pharma Inc.

View Study Details

NCT06967805Recruiting

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)...

Birmingham, ALPHASE2164 participantsMediar Therapeutics

View Study Details

NCT06968845Recruiting

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, fatal lung...

Birmingham, ALPHASE2120 participantsRein Therapeutics

View Study Details

NCT07036523Recruiting

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or ...

Birmingham, ALPHASE271 participantsBoehringer Ingelheim

View Study Details

NCT05975983Recruiting

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

The goal of this clinical trial is to learn about INS018\_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018\_055 orall...

Birmingham, ALPHASE240 participantsInSilico Medicine Hong Kong Limited

View Study Details

NCT04362644Recruiting

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed t...

Birmingham, ALPHASE110 participantsUniversity of Alabama at Birmingham

View Study Details

About Pulmonary Fibrosis Clinical Trials in Birmingham

Pulmonary fibrosis is a condition in which the lung tissue becomes damaged and scarred, making it difficult for the lungs to function properly. Idiopathic pulmonary fibrosis (IPF) is the most common form with unknown cause. Antifibrotic medications can slow progression, and lung transplant may be considered.

There are currently 11 pulmonary fibrosis clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 6,902 participants. Research is being sponsored by Duke University, Boehringer Ingelheim, United Therapeutics and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Fibrosis Clinical Trials in Birmingham — FAQ

Are there pulmonary fibrosis clinical trials in Birmingham?

Yes, there are 11 pulmonary fibrosis clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What pulmonary fibrosis treatments are being tested?

The 11 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary fibrosis.

Data updated July 16, 2026 from ClinicalTrials.gov